Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed. Giving it after surgery may kill any tumor cells that remain after surgery. It is
not yet known whether sunitinib is more effective when given before or after surgery in
treating kidney cancer.
PURPOSE: This randomized phase II trial is studying the side effects of sunitinib and to
compare how well it works when given before or after surgery in treating patients with
metastatic kidney cancer.